New Triple-Drug attack on aggressive leukemia shows promise in major trial
NCT ID NCT07407140
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a three-drug combination (venetoclax, azacitidine, and gilteritinib) followed by strong chemotherapy works better than standard chemotherapy plus gilteritinib for adults with a specific genetic type of acute myeloid leukemia (FLT3-mutated AML). About 300 people aged 14 to 74 who are healthy enough for intensive treatment will take part. The goal is to see if the new approach helps patients live longer without the cancer coming back.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML, ADULT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••